Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Arcus Biosciences, Inc. (RCUS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $24,70, with a market capitalisation of $3,06B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11,58 to $31,74. This page covers its latest market performance, valuation, price trends and company information.
$3,06B | |
$24,48 | |
$49,10 | |
$6,30 | |
$24,32 | |
13,04K | |
1,38M | |
-- | |
$31,74 | |
$11,58 | |
-- | |
-- |
Arcus Biosciences, Inc. (RCUS) is trading at $24,70 in pre-market trading as of 2026-09-16 13:08:00, up 1,56% ($0,38) from the previous close of $24,32
Pre-market trading shows how investors are pricing RCUS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Arcus Biosciences, Inc. (RCUS) moved from $29,66 to $24,70, representing a decline of 16,72% ($4,96).
The stock traded between $23,31 and $30,10 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,04 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 65,1%
RCUS is currently trading at $24,70, placing it 65,1% of the way from its 52-week low of $11,58 to its 52-week high of $31,74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 601 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Arcus Biosciences, Inc. (RCUS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.